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referral was 0.32 µg/L (range: 0.016 – 4.65 µg/L). MRI did not 
show any suspected macroscopic disease in 137 patients 
(74.9%). In 46 (25.1%) patients, MRI did indicate a local (n = 
19) and/or pelvic (n = 29) recurrence, suspected bone lesions 
were observed in two patients. The mean rPSA was 
significantly higher in patients with a suspected recurrence 
on MRI than in patients with a negative MRI (0.42 µg/L vs. 
1.35 µg/L, p = 0.00002) on a Student t-test. The mean follow-
up was 33.1 months (range: 5 – 69 months). Biochemical 
disease-free survival was significantly worse in patients with 
suspected macroscopic disease on MRI (HR 2.867, p < 0.0001) 
(see Figure), this result remained independently significant 
after Multivariate Cox regression analysis (HR 2.496, 95% CI 
1.376 – 4.528, p = 0.0003). Furthermore, androgen 
deprivation therapy-free survival was significantly worse in 
patients with a suspected recurrence on MRI (HR 4.02, p < 
0.0001), this result also remained independently significant 
after Multivariate Cox regression analysis (HR 3.4, 95% CI 
1.524 - 7.591, p = 0.003). 
In a second analysis, the location of the suspected lesions will 
be correlated to the irradiated PTVs as well as the EORTC 
guidelines. Also, the volume of the recurrence will be 






Conclusions: MRI, especially with diffusion-weighted 
sequences, detects loco-regional disease in a substantial 
subset of patients with a biochemical recurrence after 
prostatectomy, particularly when rPSA is above 0.5 µg/L. 
Lack of MRI-based dose escalation on these macroscopic 
recurrences could explain some of the biochemical 
progression observed after salvage radiotherapy. 
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To aid in radiotherapy planning for the future, a series of 
recent studies on health economic aspects of radiation 
oncology in Europe have been published by HERO - the ESTRO 
Health Economics in Radiation Oncology project. HERO has 
the overall aim to develop a knowledge base of the provision 
of radiotherapy in Europe and build a model for health 
economic evaluation of radiation treatments at the European 
level. The first step has been to provide a validated picture 
of the European radiotherapy landscape in terms of 
availability of equipment, personnel and guidelines, and to 
estimate the need for radiotherapy in European countries. 
The access to radiotherapy was studied using an 84-item 
questionnaire, distributed to the 40 countries of the 
European Cancer Observatory. The results showed a huge 
variation in the availability and sophistication of treatment 
equipment and staffing levels across Europe. The median 
number of MV units per million inhabitants was 5.3, with a 
seven-fold variation across the European countries. Staffing 
figures showed a twenty-fold variation, even after grouping 
personnel with comparable duties in the radiotherapy 
process. Guidelines for equipment and human resources were 
declared for most countries, but without explicitly providing 
metrics for developing capital and human resource 
inventories in many cases. Both staffing and access to 
modern radiotherapy (IMRT and IGRT) was correlated to 
economic status (GNI/n), but large differences were observed 
also between countries with higher GNI/n, indicating that 
health policy has a significant impact on the provision of 
services. 
The evidence-based need for radiotherapy, in terms of 
number of cancer patients requiring radiotherapy, can be 
estimated from merging epidemiological data with evidence-
based clinical decision trees. The CCORE studies based on 
Australian data have indicated that about 50% of all cancer 
patients will at some point in their disease need 
radiotherapy. In a recent European HERO study these 
estimates have been refined with details about tumour site 
and stage relevant for each of the European countries. The 
results indicate that variations in tumour site more than 
stage influence this optimal proportion; on average 51% of 
European cancer patients are candidates for radiotherapy. 
A major question which is currently being explored by HERO 
is the discrepancy observed between the actual utilization 
and the optimal utilization of radiotherapy in European 
countries. A comparison to the actually delivered 
radiotherapy courses published in the HERO studies revealed 
that the optimal radiotherapy utilization benchmark is not 
met in the vast majority of countries, not even the most 
affluent and well-served countries. Reasons for this striking 
discrepancy may in some instances be directly related to lack 
of access to radiotherapy resources, but other factors 
including local and national treatment traditions, referral 
patterns, patient preferences, geography, co-morbidity, 
reimbursement rules etc. may also play significant roles. To 
uncover these mechanisms is important for radiation 
oncology and warrants further studies. 
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Given the wide range of education programmes 
internationally, what is included within the standard scope of 
practice of Radiation Therapists (RTTs) is highly variable.  
The responsibilities of RTTs are primarily based on historical 
definitions of roles and typically refer to a basic set of 
clinical competencies.  However the professional boundaries 
of RTTs in modern radiotherapy are being challenged and 
redefined.  
Modern radiotherapy cares for a population of increasing age, 
with techniques of increasing complexity. The need for 
improved efficiency, whilst maintaining a high quality service 
has resulted in a demanding work environment for the entire 
multidisciplinary team. As such, RTTs are finding themselves 
taking on increased responsibilities in a wider range of 
clinical tasks.  RTTs today may be involved in complex 
dosimetry and planning, quality assurance, use sophisticated 
image guidance equipment and also assess and triage 
patients for toxicity assessment.  The RTTs involvement in 
education and research activities also continues to grow; 
from simply supporting their colleagues to the actual 
management of clinical trials, as an example.  In an attempt 
to formally recognise this, a number of countries have 
explored the position of Advanced Practice or Specialist 
RTTs.  This concept is more than a change in specific duties, 
but a greater level of understanding and autonomy in their 
work practice. What was once considered advanced is now 
considered standard and as such, the definition of these roles 
is also ever evolving.  What is widely recognised, however, is 
the success of such roles is dependent on a professional 
culture that supports the development of RTTs and an 
education system in place to facilitate this progression. 
Whilst the economic impact of such initiatives is difficult to 
quantify, it has been reported that through role expansion of 
the RTT there has been a decrease in patient wait times with 
improvements in access to care and development of 
innovations in clinical practice. Furthermore, this shift in 
practice has allowed for not just a more efficient use of RTTs 
but has also enabled Radiation Oncologists, Medical Physicists 
and Nursing staff to focus their efforts on development 
within their own disciplines.  
Modern radiotherapy is demanding and as such the role of the 
RTT is dynamic.  As our workforce grows and changes so too 
must our education programmes in order to meet the needs 
of the professional radiotherapy community. 
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New technologies for the radiation treatment of small 
animals allow preclinical studies using orthotopic xenograft 
models with radiochemotherapy that more closely mimic 
clinical studies. We have used an XRad 225Cx small animal 
irradiator/imager to deliver fractionated dose treatment and 
chemotherapy to early-passage orthotopically growing human 
cervix cancer xenografts in immune-deprived mice. This 
model allows assessment of both primary tumor growth and 
metastases occurring in the para-aortic lymph nodes. 
Irradiation treatment was delivered to tumours of 5-8 mm 
diameter growing in the cervix of mice using an 8-beam 
protocol with imaging of the target immediately prior to each 
fraction. The treatment plan allowed for a 1-2 mm margin 
around the imaged tumour target. The radiation treatment 
(15-20 x 2Gy fractions delivered 5 days/wk) was combined 
with weekly cisplatin (4 mg/kg/wk) to match current 
external beam treatment procedures for cervix cancers. 
Tumour growth delay analysis was performed using the 
imaging features of the irradiator to assess tumour size as a 
function of time during and after the treatment. There was 
limited response of the primary tumour to treatment with 
cisplatin alone but significant response to fractionated 
radiation treatment, which was enhanced when combined 
with cisplatin (CRTx). Additional combination treatment with 
either AMD3100, a drug that blocks the interaction of the 
CXCR4 chemokine receptor with its ligand CXCL12, or with 
Hedgehog pathway inhibitors, further enhanced the 
treatment response of the primary tumours.  Lymph nodal 
metastases in the aortic chain were also significantly 
inhibited. No significant short-term toxicities have been 
encountered to date during these studies, in particular there 
is no enhancement of the response of small intestinal stem 
cells as assessed using a GI-tract clonal assay.  
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Nitroglycerin, a nitric oxide donor agent, reduces the 
expression of hypoxia-inducible factor-1α (HIF-1α) and could 
be a normalizer of the tumor microenvironment. Both factors 
are associated with chemo-radio-resistance. Adding 
nitroglycerin to the combination of vinorelbine plus cisplatin 
has been reported to improve the overall survival (OS) of 
Asian patients with stage IIIB/IV non-small cell lung cancer 
(NSCLC) (Yasuda et al. J Clin Oncol. 2006).  Several trials 
tried to confirm that result with contradictory results. A 
Mexican phase 2 trial concluded that the addition of 
nitroglycerin to induction chemotherapy and concurrent 
chemoradiotherapy in patients with locally advanced NSCLC 
has an acceptable toxicity profile. We hypothesize that the 
contradictory results obtained were a consequence of the 
fact that a) we do not know the mechanism of action of 
nitroglycerin and b) the fact we do not have a biomarker to 
select the right patient. We further hypothesize that the 
patient with an hypoxic tumours are more likely to benefit 
form nitroglycerin patch and that nitroglycerin would act as 
inhibitor of oxidative phosphorylation by inhibition of 
complex 1. We tested these two hypothesis respectively with 
